We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genus Plc | LSE:GNS | London | Ordinary Share | GB0002074580 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.00 | 0.12% | 1,688.00 | 1,686.00 | 1,694.00 | 1,714.00 | 1,668.00 | 1,714.00 | 13,323 | 11:19:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 668.8M | 7.9M | 0.1196 | 140.97 | 1.11B |
22 October 2024
Genus plc
Chief Financial Officer Retirement
("Genus" or the "Group")
Genus (LSE: GNS), a leading global animal genetics company, announces that Alison Henriksen, Chief Financial Officer, has informed the Board of her intention to retire after five years with the Group. Alison will remain in her existing role until 31 July 2025 to assist with the transition and continue to focus on delivery of the Group's strategic priorities until her retirement.
The Board has initiated a comprehensive search for Alison's successor and will provide an update once this process has concluded.
Jorgen Kokke, Group Chief Executive Officer, commented:
"On behalf of the Board, I would like to thank Alison for her support and significant contribution to Genus's development over the last five years. Alison's financial leadership has been instrumental in Genus building a strong growth platform for many years to come. On a personal note, it has been a pleasure working with Alison, and I'm appreciative of her partnership since I joined Genus, however I fully understand her desire to create more time for family, her other interests, and to return to Australia."
For further information please contact:
Genus plc Tel: +44 125 634 5970
Jorgen Kokke, Chief Executive Officer
Alison Henriksen, Chief Financial Officer
Anand Date, Investor Relations Director
Buchanan Tel: +44 207 466 5000
Charles Ryland; Toto Berger; Sophie Wills; Verity Parker
About Genus
Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
Regulatory notes
Details of Alison's terms of departure will be consistent with Genus's existing remuneration policy and the terms will be posted on the Company's website, in accordance with section 430(2B) Companies Act 2006.
1 Year Genus Chart |
1 Month Genus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions